BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23599149)

  • 1. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements.
    Valera A; Colomo L; Martínez A; de Jong D; Balagué O; Matheu G; Martínez M; Taddesse-Heath L; Jaffe ES; Bacchi CE; Campo E
    Mod Pathol; 2013 Oct; 26(10):1329-37. PubMed ID: 23599149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT3 pathway is activated in ALK-positive large B-cell lymphoma carrying SQSTM1-ALK rearrangement and provides a possible therapeutic target.
    d'Amore ES; Visco C; Menin A; Famengo B; Bonvini P; Lazzari E
    Am J Surg Pathol; 2013 May; 37(5):780-6. PubMed ID: 23588372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.
    Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez de Villambrosia S; Loghavi S; Gomez Mediavilla A; Tonda R; Beltran S; Gut M; Pereña Gonzalez A; d'Ámore E; Visco C; Khoury JD; Montes-Moreno S
    Haematologica; 2021 Apr; 106(4):1120-1128. PubMed ID: 32273478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion.
    Momose S; Tamaru J; Kishi H; Mikata I; Mori M; Toyozumi Y; Itoyama S
    Hum Pathol; 2009 Jan; 40(1):75-82. PubMed ID: 18755494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas.
    Rodig SJ; Kutok JL; Paterson JC; Nitta H; Zhang W; Chapuy B; Tumwine LK; Montes-Moreno S; Agostinelli C; Johnson NA; Ben-Neriah S; Farinha P; Shipp MA; Piris MA; Grogan TM; Pileri SA; Gascoyne RD; Marafioti T
    Haematologica; 2010 Dec; 95(12):2056-62. PubMed ID: 20823132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.
    Abate F; Todaro M; van der Krogt JA; Boi M; Landra I; Machiorlatti R; Tabbò F; Messana K; Abele C; Barreca A; Novero D; Gaudiano M; Aliberti S; Di Giacomo F; Tousseyn T; Lasorsa E; Crescenzo R; Bessone L; Ficarra E; Acquaviva A; Rinaldi A; Ponzoni M; Longo DL; Aime S; Cheng M; Ruggeri B; Piccaluga PP; Pileri S; Tiacci E; Falini B; Pera-Gresely B; Cerchietti L; Iqbal J; Chan WC; Shultz LD; Kwee I; Piva R; Wlodarska I; Rabadan R; Bertoni F; Inghirami G;
    Leukemia; 2015 Jun; 29(6):1390-401. PubMed ID: 25533804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.
    Chapman JR; Bouska AC; Zhang W; Alderuccio JP; Lossos IS; Rimsza LM; Maguire A; Yi S; Chan WC; Vega F; Song JY
    Br J Haematol; 2021 Sep; 194(5):870-878. PubMed ID: 34272731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas.
    Valera A; Balagué O; Colomo L; Martínez A; Delabie J; Taddesse-Heath L; Jaffe ES; Campo E
    Am J Surg Pathol; 2010 Nov; 34(11):1686-94. PubMed ID: 20962620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Myc dysregulation is a co-transforming event for nuclear factor-κB activated B cells.
    David A; Arnaud N; Fradet M; Lascaux H; Ouk-Martin C; Gachard N; Zimber-Strobl U; Feuillard J; Faumont N
    Haematologica; 2017 May; 102(5):883-894. PubMed ID: 28232371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diffuse large B-cell lymphoma with expression of anaplastic lymphoma kinase protein: clinicopathologic and immunohistochemical study of 5 cases].
    Wang WY; Ma ZG; Li GD; Liu WP; Zhong L; Wang Y; Li JM; Li L; Jiang W; Tang Y; Liao DY
    Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):529-34. PubMed ID: 17134546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Lai R; Rassidakis GZ; Medeiros LJ; Ramdas L; Goy AH; Cutler C; Fujio Y; Kunisada K; Amin HM; Gilles F
    Am J Pathol; 2004 Jun; 164(6):2251-8. PubMed ID: 15161657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway.
    Anastasov N; Bonzheim I; Rudelius M; Klier M; Dau T; Angermeier D; Duyster J; Pittaluga S; Fend F; Raffeld M; Quintanilla-Martinez L
    Haematologica; 2010 May; 95(5):760-7. PubMed ID: 20015877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual ALK and MYC rearrangements leading to an aggressive variant of anaplastic large cell lymphoma.
    Liang X; Branchford B; Greffe B; McGavran L; Carstens B; Meltesen L; Albano EA; Quinones R; Cook B; Graham DK
    J Pediatr Hematol Oncol; 2013 Jul; 35(5):e209-13. PubMed ID: 23619105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Frequency of Double Expresser in Selected Cases of High Grade Diffuse Large B-Cell Lymphomas.
    Naseem M; Asif M; Khadim MT; Ud-Din H; Jamal S; Shoaib I
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1103-1107. PubMed ID: 32334477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge.
    Montes-Moreno S; Montalbán C; Piris MA
    Leuk Lymphoma; 2012 Feb; 53(2):185-94. PubMed ID: 21812534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
    Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
    Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
    Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].
    Zhang XY; Ma ZP; Cui WL; Pang XL; Chen R; Wang L; Zhang W; Li XX
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):25-31. PubMed ID: 29325247
    [No Abstract]   [Full Text] [Related]  

  • 19. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.
    Pasqualucci L; Compagno M; Houldsworth J; Monti S; Grunn A; Nandula SV; Aster JC; Murty VV; Shipp MA; Dalla-Favera R
    J Exp Med; 2006 Feb; 203(2):311-7. PubMed ID: 16492805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas.
    Raetz EA; Perkins SL; Carlson MA; Schooler KP; Carroll WL; Virshup DM
    Am J Pathol; 2002 Sep; 161(3):875-83. PubMed ID: 12213716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.